AMANDA BAGWELL: Open Payments
NPI 1235806589 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$307 in 13 payments from 8 companies in 2025. Trend: 2023 $18 · 2024 $22 · 2025 $307
Food & beverage: $307
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $90 |
| Lilly USA, LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| PFIZER INC. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: VRAYLAR, CAPLYTA, GATTEX, MOUNJARO, TRUMENBA, Jornay PM, Veozah, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
